S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:CRTX

Cortexyme (CRTX) Stock Price, News & Analysis

$1.13
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$1.06
$1.16
50-Day Range
$1.13
$1.40
52-Week Range
$1.78
$40.66
Volume
60,549 shs
Average Volume
620,672 shs
Market Capitalization
$34.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CRTX stock logo

About Cortexyme Stock (NASDAQ:CRTX)

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

CRTX Stock Price History

CRTX Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
See More Headlines
Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:CRTX
CUSIP
21924P10
Fax
N/A
Employees
55
Year Founded
2012

Profitability

Net Income
$-89,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
21,739,000
Market Cap
$34.07 million
Optionable
Not Optionable
Beta
1.40

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Leslie J. Holsinger Ph.D. (Age 57)
    Exec. VP of R&D
    Comp: $603.85k
  • Dr. Dirk Thye M.D. (Age 52)
    CEO & Director
  • Mr. Ted Monohon (Age 56)
    VP of Fin., Principal Financial Officer & Chief Accounting Officer
  • Mr. Brendan Hannah M.B.A.
    Chief Bus. Officer
  • Dr. Karen L. Smith L.L.M (Age 54)
    L.L.M., M.B.A., M.D., PH.D., Chief Medical Officer

CRTX Stock Analysis - Frequently Asked Questions

How have CRTX shares performed in 2024?

Cortexyme's stock was trading at $1.05 at the start of the year. Since then, CRTX stock has increased by 7.6% and is now trading at $1.13.
View the best growth stocks for 2024 here
.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) posted its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.05.

What other stocks do shareholders of Cortexyme own?
When did Cortexyme IPO?

Cortexyme (CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners